<SEC-DOCUMENT>0001299933-13-001100.txt : 20130610
<SEC-HEADER>0001299933-13-001100.hdr.sgml : 20130610
<ACCEPTANCE-DATETIME>20130610165026
ACCESSION NUMBER:		0001299933-13-001100
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20130606
ITEM INFORMATION:		Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20130610
DATE AS OF CHANGE:		20130610

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			STEMCELLS INC
		CENTRAL INDEX KEY:			0000883975
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				943078125
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-19871
		FILM NUMBER:		13903961

	BUSINESS ADDRESS:	
		STREET 1:		3155 PORTER DRIVE
		STREET 2:		.
		CITY:			PALO ALTO
		STATE:			CA
		ZIP:			94304
		BUSINESS PHONE:		6504753100

	MAIL ADDRESS:	
		STREET 1:		3155 PORTER DRIVE
		STREET 2:		.
		CITY:			PALO ALTO
		STATE:			CA
		ZIP:			94304

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	CYTOTHERAPEUTICS INC/DE
		DATE OF NAME CHANGE:	19930328
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>htm_47904.htm
<DESCRIPTION>LIVE FILING
<TEXT>
<!-- CoverPageHeader start -->
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 3.2//EN">
<HTML>
<HEAD>
<TITLE> StemCells, Inc. (Form: 8-K) </TITLE>
</HEAD>
<BODY TEXT="#000000" BGCOLOR="#FFFFFF" ALINK="#0000FF" HLINK="#FF0000" VLINK="#800080">
<!-- Comment1 -->
<A NAME="DOCUMENT_TOP">&nbsp;</A>
<P>
<!-- CoverPageHeader end --><!-- CoverPageTitle START -->
<A NAME="DOCUMENT_TOP">&nbsp;</A>
<HR NOSHADE>
<P>
<P ALIGN="CENTER">
<FONT SIZE="4">
		UNITED STATES<BR>
	SECURITIES AND EXCHANGE COMMISSION
</FONT>
<BR>
<FONT SIZE="2">
	WASHINGTON, D.C. 20549
</FONT>
<P ALIGN="CENTER">
<FONT SIZE="5">
	FORM 8-K
</FONT>
<FONT SIZE="2">

</FONT>
</P>
<P ALIGN="CENTER">
<FONT SIZE="3">
	CURRENT REPORT
</FONT>
</P>
<P ALIGN="CENTER">
<FONT SIZE="2">
	Pursuant to Section&nbsp;13 or 15(d) of the Securities Exchange Act of 1934
</FONT>
</P>
<CENTER>
<TABLE CELLSPACING="0" BORDER="0" CELLPADDING="0" WIDTH="100%">
<TR VALIGN="BOTTOM">
<TD WIDTH="51%">
	&nbsp;
</TD>
<TD WIDTH="5%">
	&nbsp;
</TD>
<TD WIDTH="44%">
	&nbsp;
</TD>
</TR>
<TR VALIGN="BOTTOM">
<TD ALIGN="CENTER" VALIGN="TOP">
<FONT SIZE="2">
	Date of Report (Date of Earliest Event Reported):
</FONT>
</TD>
<TD>
<FONT SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<FONT SIZE="2">
	June 6, 2013
</FONT>
</TD>
</TR>
</TABLE>
<BR>
</CENTER>
<!-- CoverPageTitle END --><!-- CoverPageRegistrant START -->
<P ALIGN="CENTER"><!-- -->
<FONT SIZE="6">
	StemCells, Inc.
</FONT>
<FONT SIZE="2">
<BR>__________________________________________<BR>
	(Exact name of registrant as specified in its charter)
</FONT>
<CENTER>
<TABLE CELLSPACING="0" BORDER="0" CELLPADDING="0" WIDTH="100%">
<TR VALIGN="BOTTOM">
<TD WIDTH="33%">
	&nbsp;
</TD>
<TD WIDTH="34%">
	&nbsp;
</TD>
<TD WIDTH="33%">
	&nbsp;
</TD>
</TR>
<TR VALIGN="BOTTOM">
<TD ALIGN="CENTER" VALIGN="TOP">
<FONT SIZE="2">
	Delaware
</FONT>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<FONT SIZE="2">
	000-19871
</FONT>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<FONT SIZE="2">
	94-3078125
</FONT>
</TD>
</TR>
<TR VALIGN="BOTTOM">
<TD ALIGN="CENTER" VALIGN="TOP">
<FONT SIZE="2">
_____________________<BR>
	(State or other jurisdiction
</FONT>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<FONT SIZE="2">
_____________<BR>
	(Commission
</FONT>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<FONT SIZE="2">
______________<BR>
	(I.R.S. Employer
</FONT>
</TD>
</TR>
<TR VALIGN="BOTTOM">
<TD ALIGN="CENTER" VALIGN="TOP">
<FONT SIZE="2">
	of incorporation)
</FONT>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<FONT SIZE="2">
	File Number)
</FONT>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<FONT SIZE="2">
	Identification No.)
</FONT>
</TD>
</TR>
<TR VALIGN="BOTTOM">
<TD ALIGN="CENTER" VALIGN="TOP">
<FONT SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<FONT SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<FONT SIZE="2">
	&nbsp;
</FONT>
</TD>
</TR>
<TR VALIGN="BOTTOM">
<TD ALIGN="CENTER" VALIGN="TOP">
<FONT SIZE="2">
	7707 Gateway Blvd, Suite 140, Newark, California
</FONT>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<FONT SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<FONT SIZE="2">
	94560
</FONT>
</TD>
</TR>
<TR VALIGN="BOTTOM">
<TD ALIGN="CENTER" VALIGN="TOP">
<FONT SIZE="2">
_________________________________<BR>
	(Address of principal executive offices)
</FONT>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<FONT SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<FONT SIZE="2">
___________<BR>
	(Zip Code)
</FONT>
</TD>
</TR>
</TABLE>
</CENTER>
<CENTER>
<TABLE CELLSPACING="0" BORDER="0" CELLPADDING="0" WIDTH="100%">

<TR VALIGN="BOTTOM">
<TD WIDTH="51%">
	&nbsp;
</TD>
<TD WIDTH="5%">
	&nbsp;
</TD>
<TD WIDTH="44%">
	&nbsp;
</TD>
</TR>
<TR VALIGN="BOTTOM">
<TD ALIGN="CENTER" VALIGN="TOP">
<FONT SIZE="2">
	Registrant&#146;s telephone number, including area code:
</FONT>
</TD>
<TD>
<FONT SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<FONT SIZE="2">
	510.456.4000
</FONT>
</TD>
</TR>
</TABLE>
</CENTER>
<P ALIGN="CENTER">
<FONT SIZE="2">
	Not Applicable
<BR>______________________________________________<BR>
	Former name or former address, if changed since last report
</FONT>
<P ALIGN="CENTER">
<FONT SIZE="2">
	&nbsp;
</FONT>
<!-- CoverPageRegistrant END --><P><FONT SIZE="2">
Check the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant under any
of the following provisions:</FONT>
</P>
<P><FONT SIZE="2">
[&nbsp;&nbsp;]&nbsp;&nbsp;Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)<br>
[&nbsp;&nbsp;]&nbsp;&nbsp;Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)<br>
[&nbsp;&nbsp;]&nbsp;&nbsp;Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))<br>
[&nbsp;&nbsp;]&nbsp;&nbsp;Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))<br>
</P></FONT><!-- PageBreak START -->
<P>
<HR NOSHADE>
<DIV ALIGN="LEFT" STYLE="PAGE-BREAK-BEFORE:ALWAYS">
<A HREF="#DOCUMENT_TOP">
<U>
<B>
<FONT SIZE="2">Top of the Form</FONT>
</B>
</U>
</A>
</DIV>
<!-- PageBreak END -->



<P align="left" style="font-size: 10pt"><FONT style="font-size: 11pt"><B>Item&nbsp;5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of
Certain Officers; Compensatory Arrangements of Certain Officers.</B>
</FONT>

<P align="left" style="font-size: 11pt">Earlier today, StemCells, Inc. (the &#147;Company&#148;) issued a press release announcing the hire of three
new employees into product development roles at the Company and the creation of a new corporate
function responsible for establishing scientific and strategic alliances and for building on the
Company&#146;s existing stem cell technology platform. A copy of the press release is attached hereto
as Exhibit&nbsp;99.1.


<P align="left" style="font-size: 11pt"><B><I>Appointment of New Executive Vice President and Head of Research and Development</I></B>


<P align="left" style="font-size: 11pt">On June&nbsp;10, 2013, the Company announced the appointment of Eliseo Oreste Salinas, MD, MSc, to the
position of Executive Vice President and Head of Research and Development, effective immediately.
Dr.&nbsp;Salinas brings more than 22&nbsp;years of research, clinical translation, and product development
experience. Prior to joining the Company, Dr.&nbsp;Salinas served as Executive Vice President, Head of
Development and Chief Medical Officer of Elan Pharmaceuticals. Before joining Elan, Dr.&nbsp;Salinas
held senior management positions at Shire plc, Adolor Corporation and Wyeth-Ayerst Research. In
his new role at the Company as EVP and Head of Research and Development, Dr.&nbsp;Salinas will be
responsible for the Company&#146;s research, product development and clinical translation activities.
He will serve on the Company&#146;s Executive Officer Committee and report directly to the Company&#146;s
Chief Executive Officer.


<P align="left" style="font-size: 11pt"><B><I>Appointment of New Executive Vice President, Scientific and Strategic Alliances</I></B>


<P align="left" style="font-size: 11pt">Pursuant to Company action taken on June&nbsp;6, 2013, the Company has appointed Ann Tsukamoto, PhD, to
the position of Executive Vice President, Scientific and Strategic Alliances. Previously,
Dr.&nbsp;Tsukamoto served as the Company&#146;s Executive Vice Present of Research and Development, a
position she held since September&nbsp;2008. In her new role, Dr.&nbsp;Tsukamoto will be responsible for
developing the Company&#146;s alliances with research institutions, corporations, government agencies,
and disease foundations. She will continue to serve on the Company&#146;s Executive Officer Committee
and report directly to the Company&#146;s Chief Executive Officer.


<P align="left" style="font-size: 11pt"><B>Item&nbsp;9.01 Financial Statements and Exhibits.</B>


<P align="left" style="font-size: 11pt">(c)&nbsp;Exhibits.


<P align="left" style="font-size: 11pt">Exhibit&nbsp;99.1 Press Release, dated June&nbsp;10, 2013, announcing new hires and creation of new executive
function at the Company.



<P align="center" style="font-size: 10pt; display: none">




<!-- v.121908 -->

<!-- PageBreak START -->
<P>
<HR NOSHADE>
<DIV ALIGN="LEFT" STYLE="PAGE-BREAK-BEFORE:ALWAYS">
<A HREF="#DOCUMENT_TOP">
<U>
<B>
<FONT SIZE="2">Top of the Form</FONT>
</B>
</U>
</A>
</DIV>
<!-- PageBreak END --><!-- SignatureHeader START -->
<P ALIGN="CENTER">
<FONT SIZE="2">
<B>
	SIGNATURES
</B>
</FONT>
</P>
<P ALIGN="LEFT">
<FONT SIZE="2">
	Pursuant to the requirements of the Securities Exchange Act of 1934, the
	registrant has duly caused this report to be signed on its behalf by the
	undersigned hereunto duly authorized.
</FONT>
</P>
<!-- SignatureHeader END --><!-- Signature START -->
<CENTER>
<TABLE CELLSPACING="0" BORDER="0" CELLPADDING="0" WIDTH="100%">
<TR VALIGN="BOTTOM">
<TD WIDTH="19%">
	&nbsp;
</TD>
<TD WIDTH="34%">
	&nbsp;
</TD>
<TD WIDTH="3%">
	&nbsp;
</TD>
<TD WIDTH="1%">
	&nbsp;
</TD>
<TD WIDTH="43%">
	&nbsp;
</TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP">
<FONT SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD COLSPAN="3" VALIGN="TOP" ALIGN="LEFT">
<FONT SIZE="2">
	StemCells, Inc.
</FONT>
</TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP">
<FONT SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD>
<FONT SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<FONT SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<FONT SIZE="2">
	&nbsp;
</FONT>
</TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP">
<FONT SIZE="2">
<I>
	June 10, 2013
</I>
</FONT>
</TD>
<TD>
<FONT SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<FONT SIZE="2">
<I>
	By:
</I>
</FONT>
</TD>
<TD>
<FONT SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<FONT SIZE="2">
<I>
	/s/ Ken Stratton
</I>
<BR>
</FONT>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<FONT SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<FONT SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<HR SIZE="1" NOSHADE>
</TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP">
<FONT SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<FONT SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<FONT SIZE="2">
<I>
	Name: Ken Stratton
</I>
</FONT>
</TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP">
<FONT SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<FONT SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<FONT SIZE="2">
<I>
	Title: General Counsel
</I>
</FONT>
</TD>
</TR>
</TABLE>
</CENTER>
<!-- Signature END --><!-- PageBreak START -->
<P>
<HR NOSHADE>
<DIV ALIGN="LEFT" STYLE="PAGE-BREAK-BEFORE:ALWAYS">
<A HREF="#DOCUMENT_TOP">
<U>
<B>
<FONT SIZE="2">Top of the Form</FONT>
</B>
</U>
</A>
</DIV>
<!-- PageBreak END --><P ALIGN="CENTER">
<FONT SIZE="2">
	Exhibit&nbsp;Index
</FONT>
<CENTER>
<TABLE CELLSPACING="0" BORDER="0" CELLPADDING="0" WIDTH="60%">
<TR VALIGN="BOTTOM">
<TD WIDTH="8%">
	&nbsp;
</TD>
<TD WIDTH="15%">
	&nbsp;
</TD>
<TD WIDTH="77%">
	&nbsp;
</TD>
</TR>

<BR>
<TR VALIGN="BOTTOM">
<TD NOWRAP ALIGN="LEFT">
<FONT SIZE="1">
<B>
	Exhibit No.
</B>
</FONT>
</TD>
<TD>
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP ALIGN="LEFT">
<FONT SIZE="1">
<B>
	Description
</B>
</FONT>
</TD>
</TR>
<TR VALIGN="BOTTOM">
<TD NOWRAP ALIGN="CENTER">
<HR SIZE="1" NOSHADE>
</TD>
<TD>
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP ALIGN="CENTER">
<HR ALIGN="LEFT" SIZE="1" WIDTH="88%" NOSHADE>
</TD>
</TR>





<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" WIDTH="8%" nowrap>
<FONT SIZE="2">
<DIV ALIGN="LEFT">
	99.1
</DIV>
</FONT>
</TD>
<TD WIDTH="15%">
<FONT SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP" WIDTH="77%">
<FONT SIZE="2">
Press release dated June 10, 2013
</FONT>
</TD>
</TR></TABLE></CENTER><!-- HTMLFooter START -->
</BODY>
</HTML>
<!-- HTMLFooter END -->
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>exhibit1.htm
<DESCRIPTION>EX-99.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 3.2//EN">
<HTML>
<HEAD>
<TITLE> EX-99.1 </TITLE>
</HEAD>
<BODY TEXT="#000000" BGCOLOR="#FFFFFF" ALINK="#0000FF" HLINK="#FF0000" VLINK="#800080">

<BODY style="font-family: 'Times New Roman',Times,serif">


<P align="left" style="font-size: 10pt"><FONT style="font-size: 11pt"><img src="e38374-1316113375349d9a92_1.jpg">
</FONT>

<P align="center" style="font-size: 11pt"><B>STEMCELLS, INC. STRENGTHENS PRODUCT DEVELOPMENT TEAM AND APPOINTS<BR>
EXECUTIVE TO FOCUS ON SCIENTIFIC AND STRATEGIC ALLIANCES</B>



<P align="left" style="font-size: 11pt"><B>NEWARK, Calif. (June&nbsp;10, 2013) </B>&#150; StemCells, Inc. (Nasdaq: STEM) today announced key hires to
strengthen its product development capabilities and announced the creation of a new corporate
function responsible for establishing scientific and strategic alliances and for building on the
Company&#146;s existing stem cell technology platform.


<P align="left" style="font-size: 11pt">Eliseo Salinas, M.D., has joined the Company as Executive Vice President and Head of Research and
Development, and will be responsible for the Company&#146;s research, product development and clinical
translation activities. Dr.&nbsp;Salinas will report to Martin McGlynn, President and CEO of the
Company.


<P align="left" style="font-size: 11pt">Ann Tsukamoto, Ph.D., who has most recently served as the Company&#146;s Executive Vice President of
Research and Development, will assume the new role of Executive Vice President, Scientific and
Strategic Alliances, responsible for developing the Company&#146;s alliances with research institutions,
corporations, government agencies and disease foundations. Dr.&nbsp;Tsukamoto will continue to report
to Mr.&nbsp;McGlynn.


<P align="left" style="font-size: 11pt">The Company also announced that Nicki Vasquez, Ph.D., has joined the Company as Vice President of
Program and Portfolio Management, and Allyson Gage, Ph.D., has joined as Senior Director of
Clinical Development.


<P align="left" style="font-size: 11pt">&#147;The Company&#146;s clinical trials have so far been single-arm open-label studies, involving a small
number of patients and conducted at one or two clinical sites,&#148; said Mr.&nbsp;McGlynn. &#147;These trials,
however, have generated a growing body of encouraging human data, providing us with strong
rationale to begin preparing for controlled, Phase II, proof of concept studies in multiple disease
indications, involving larger patient numbers and multiple trial sites internationally. The
addition of Eliseo, Nicki and Allyson is an integral part of our strategy to ensure we have the
expertise and bandwidth to succeed in this next step of the Company&#146;s path to market approval.


<P align="left" style="font-size: 11pt">&#147;Meanwhile, I am delighted to have Ann assume the role of EVP for Scientific and Strategic
Alliances. This will be Ann&#146;s fifth leadership role here at StemCells, and there is no one better
qualified to take charge of building on our existing relationships with state and federal agencies,
such as the National Institutes of Health and the California Institute for Regenerative Medicine,
and with other important stakeholders, such as the International Society for Stem Cell Research and
the various disease foundations. In addition, Ann will play an important role in helping us stay
abreast of the rapidly evolving scientific and technological developments that could have
far-reaching implications for the Company&#146;s long-term success.&#148;


<P align="left" style="font-size: 11pt">Dr.&nbsp;Tsukamoto has been a groundbreaking researcher in the field of stem cell biology for more than
twenty years. She joined the Company in February&nbsp;1998 as Senior Director, Scientific Operations,
and has held several leadership roles at the Company, most recently as Executive Vice President of
Research and Development since September&nbsp;2008. Dr.&nbsp;Tsukamoto was a co-discoverer of the human
hematopoietic stem cell while at SyStemix, Inc., and played a leading role at StemCells in the
isolation of the human neural stem cell as well as populations of human liver and pancreatic cells
with stem cell-like properties. Dr.&nbsp;Tsukamoto received her doctorate from the University of
California, Los Angeles, and did postdoctoral research at the University of California, San
Francisco.


<P align="left" style="font-size: 11pt">In his new role, Dr.&nbsp;Salinas will focus on accelerating completion of the Company&#146;s ongoing trials
in spinal cord injury and age-related macular degeneration, as well as advancing the Company&#146;s
plans for a Phase&nbsp;II study in Pelizaeus-Merzbacher disease. Dr.&nbsp;Salinas has more than 20&nbsp;years of
experience and expertise developing therapeutic products for central nervous system (CNS)&nbsp;disorders
in many key jurisdictions worldwide, including the United States, Canada, the European Union, and
Japan. Under his leadership, 15 programs obtained regulatory approval in the United States and
other major international markets. Prior to joining StemCells, Dr.&nbsp;Salinas was Executive Vice
President, Head of Development, and Chief Medical Officer of Elan Pharmaceuticals. Before joining
Elan, Dr.&nbsp;Salinas was Senior Vice President, Research and Development and Chief Medical Officer of
Adolor Corporation; Executive Vice President, Speciality Pharma, Research and Development and Chief
Scientific Officer of Shire plc; and held roles of increasing responsibility in research and
development at Wyeth-Ayerst Research, including head of worldwide CNS product development. Dr.
Salinas earned his medical degree from the University of Buenos Aires, Argentina, performed a
residency in psychiatry in Paris at the Clinique des Maladies Mentales et de l&#146;Enc&#233;phale, and
obtained a master&#146;s degree in pharmacology from the Universit&#233; Pierre et Marie Curie, Acad&#233;mie de
Paris, France.


<P align="left" style="font-size: 11pt">Both Drs.&nbsp;Vasquez and Gage are experts in product development in the biotech industry. Dr.&nbsp;Vasquez
was most recently Vice President, Global Development Program & Portfolio Management at Elan
Pharmaceuticals. She earned her doctorate in immunology and bachelor&#146;s degree in microbiology from
the University of California, San Diego. Dr.&nbsp;Gage has held senior roles in clinical development at
Elan and Forest Laboratories, Inc. She earned her doctorate and master&#146;s degree in neuroscience
from Albert Einstein College of Medicine.


<P align="left" style="font-size: 11pt">In connection with their hire, the Company has granted Drs.&nbsp;Salinas, Vasquez and Gage an aggregate
total of 496,965 restricted stock units (RSUs). Each grant was made pursuant to the Company&#146;s 2012
Commencement Incentive Plan and in accordance with Nasdaq Listing Rule&nbsp;5635(c)(4) concerning
inducement grants to new employees. Each RSU gives the holder the right to receive upon vesting,
without cash payment, a share of StemCells common stock. With the exception of 11,765 RSUs, which
vested three days after grant, all of these granted RSUs have four-year vesting schedules so that
they vest in four equal parts on each of their first four service anniversaries, starting in 2014
and ending in 2017.


<P align="left" style="font-size: 11pt"><B>About StemCells, Inc.</B>


<P align="left" style="font-size: 11pt">StemCells, Inc. is engaged in the research, development, and commercialization of cell-based
therapeutics and tools for use in stem cell-based research and drug discovery. The Company&#146;s lead
therapeutic product candidate, HuCNS-SC&#174; cells (purified human neural stem cells), is currently in
development as a potential treatment for a broad range of central nervous system disorders. &nbsp;In a
Phase&nbsp;I clinical trial in Pelizaeus-Merzbacher disease (PMD), a fatal myelination disorder in
children, the Company has shown preliminary evidence of progressive and durable donor-derived
myelination in all four patients transplanted with HuCNS-SC cells. The Company is also conducting
a Phase I/II clinical trial in chronic spinal cord injury in Switzerland and has reported positive
interim data for the first three patients. The Company has also initiated a Phase I/II clinical
trial in dry age-related macular degeneration (AMD), and is pursuing preclinical studies in
Alzheimer&#146;s disease.&nbsp; StemCells also markets stem cell research products, including media and
reagents, under the SC Proven&#174; brand. Further information about StemCells is available at
<U>http://www.stemcellsinc.com</U>.


<P align="left" style="font-size: 11pt"><I>Apart from statements of historical fact, the text of this press release constitutes
forward-looking statements within the meaning of the Securities Act of 1933, as amended, and the
Securities Exchange Act of 1934, as amended, and is subject to the safe harbors created therein.
These statements include, but are not limited to, statements regarding the timing and prospect of
initiating a Phase II clinical trial in PMD and concluding the Company&#146;s on-going trials in spinal
cord injury and AMD; the Company&#146;s ability to successfully execute its product development
activities; and the future business operations of the Company. These forward-looking statements
speak only as of the date of this news release. The Company does not undertake to update any of
these forward-looking statements to reflect events or circumstances that occur after the date
hereof. Such statements reflect management&#146;s current views and are based on certain assumptions
that may or may not ultimately prove valid. The Company&#146;s actual results may vary materially from
those contemplated in such forward-looking statements due to risks and uncertainties to which the
Company is subject, including the fact that additional trials will be required to demonstrate the
safety and efficacy of the Company&#146;s HuCNS-SC cells for the treatment of any disease or disorder;
uncertainty as to whether the FDA, Health Canada or other applicable regulatory agencies will
permit the Company to continue clinical testing in spinal cord injury, AMD or in future clinical
trials of proposed therapies for other diseases or conditions; uncertainties regarding the
Company&#146;s ability to obtain the increased capital resources needed to continue its current and
planned research and development operations; uncertainty as to whether HuCNS-SC cells and any
products that may be generated in the future in the Company&#146;s cell-based programs will prove safe
and clinically effective and not cause tumors or other adverse side effects; uncertainties
regarding the Company&#146;s ability to commercialize a therapeutic product and its ability to
successfully compete with other products on the market; and other factors that are described under
the heading &#147;Risk Factors&#148; in the Company&#146;s Annual Report on </I><I>Form 10-K</I><I> for the year ended December
31, 2012, and in its subsequent reports on </I><I>Form 10-Q</I><I> and </I><I>Form 8-K</I><I>.</I>


<P align="left" style="font-size: 11pt">CONTACT:


<P align="left" style="font-size: 11pt">Rodney Young
<BR>
StemCells, Inc.
<BR>
Chief Financial Officer
<BR>
(510)&nbsp;456-4128


<P align="left" style="font-size: 11pt">Ian Stone
<BR>
Russo Partners
<BR>
(619)&nbsp;308-6541



<P align="center" style="font-size: 10pt; display: none">




<!-- v.121908 -->
</BODY>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>e38374-1316113375349d9a92_1.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 e38374-1316113375349d9a92_1.jpg
M_]C_X``02D9)1@`!`0```0`!``#_VP!#``$!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0'_
MVP!#`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0'_P``1"``[`2@#`2(``A$!`Q$!_\0`
M'P```04!`0$!`0$```````````$"`P0%!@<("0H+_\0`M1```@$#`P($`P4%
M!`0```%]`0(#``01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T?`D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0`'P$``P$!`0$!
M`0$!`0````````$"`P0%!@<("0H+_\0`M1$``@$"!`0#!`<%!`0``0)W``$"
M`Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O`58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H`#`,!``(1`Q$`/P#^_BBO$_C]
M^T7\$OV7?AYJ'Q5^/?Q%T'X:^!M.F2S.K:Y+.\^I:E-%//;Z-H&C6$%YK7B3
M7;F"VN9[71=!T[4=3G@M;JXCM6@MIY(_Q'UG_@YH_8`TO4I;&R\`_M1^(K6.
M9XDUC1_A]\.;?3[E%?:MQ!#X@^+^B:LL,B_O%6XTR"X5.)(8WR@^DR7A#BCB
M*G4K9)D68YE0I2<)U\-AY2H1FK-P]M+EI.HDTW",W-)IM6:/`S;BGAW(JD*6
M;YQ@<!6FE*-&M67MG%[3=&'-44'K:<HJ+L[/1G]$E%?FY^P__P`%5?V3/V_]
M=\0>#_@?JWCG3?'WAC0)?%>K^!?'_@^?0=9B\,6^HZ9I%QKL.HZ5>>(?"5S:
MP:KK.F6$EO!XE?4UFNXG-A]FS./4_P!J?_@H3^R%^Q1JWA#0OVF?BTWPVU3Q
MYIVJZKX4MO\`A`OB9XR_M73]%N;2TU.X\_P#X-\4V]C]FN+ZUC\K4I;.>;S=
M\$<J)(R<M7AS/Z.:O(YY+FG]LI.7]EQP6(J8Z452=9SAAJ=.=6I#V,95>>$9
M0]G%SORILZ*>?Y)5RU9Q#-LO_LIR4?[0EBJ-/"*;J*DH2K5)1A";J2C3Y)M2
MYVHVNTC[0HK\@O\`A_/_`,$H_P#HZ9__``QW[1O_`,Z*C_A_/_P2C_Z.F?\`
M\,=^T;_\Z*N__4;C7_HD.)__``PYI_\`,IQ?ZX\)?]%/D'_AWP'E_P!/_-'Z
M^T5^</P%_P""MO\`P3Z_:<^+'A3X'_!#X^MXU^*'C?\`MS_A&/#)^%7QJ\-C
M4_\`A&_#>L>+M:_XG7BWX<Z#X>LOL?A[0-6U#_B8:K:?:/LGV2U\^^GMK:;]
M&I)(X8WEFD2..-&DDDD941$0%F=V8A555Y9B0`!DFO%S'*LTRBO'"YKEV/RW
M$SIQK0P^/PE?!UY4IRE"-6-+$4Z=1TY3A.,9J+BY0DDVXM'KX',\NS2A+$Y;
MC\'C\/";IRKX/$T<31C4C&,Y4Y5*,YPC.,)PE*+:DHRBVK-$E%?E7XT_X+;?
M\$N_`7B35?">O?M7>'[G5M'N9+2]F\)^`/B_X^T(SQ.T<@L?%7@7X?>(_"^J
MHKHP\_2]8O(#P5D(()Y;_A_/_P`$H_\`HZ9__#'?M&__`#HJ]>GP5QE5A"I3
MX3XEJ4ZD8SA.&1YG*$XR5XRC*.%<91::::;36J9Y4^+^%*<Y4Y\2Y%"<).$X
M2S;`QE&2=G&2=>Z:;LT]4]S]?:*\4_9\_:)^#O[5'PMT3XT_`?Q>?'/PT\17
MFM6&C^)#X?\`$_A@WEWX>U:[T/6(O['\8:+X?UZW^R:I8W5MONM+@CN/*\^U
M>:W>.5_:L\^V,]\_Y_6OG\1AZ^$KUL+BJ-7#8G#U9T<1AZ].=&O0K4I.%2E6
MI5%&=.I3FG&<)Q4HR3C))JQ[M"O0Q-&EB</6IU\/7IPJT:]&<:E*K2J14H5*
M=2#<)PG%J491;3333L+17Y>^#/\`@L5^P1X\_:5'[*OA_P"+-^_Q+N?&5W\.
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MH*]ZJH<WM'"R;NH[)O9-KZSICND2L\CJB*&9F8A51%&6+$\!5`)+'``Y-.SS
MC\OZYK\>_P#@H9^U5J5I?7?[/WP[U&XM7>UB3XD:OITDL5W*-2@\R'P5;2I&
MC""XLI[>YUY[65UNH;R'199`G]K6DGY]QUQKE?`7#V)S[-.:IR2CA\#@J32Q
M&88^JG[#"4+WLY<LIU)V:I485*EI<JB^7/,ZPF0Y?5Q^*;:BU"C1B[5,17E\
M%&&Z3=G*4GI&$92=[6?I7[1/_!1SPIX"O;_PE\'=.L?'GB2T>>UO_$U[-(/!
MNEW<8"K'9"U=+GQ--'+YB3FUN-/TV,K&8-2OB988?BJP\?\`_!0+]HJ1=6\*
M7GQ*DT>=I$LI_"8@^'GA8`%M\5OK"R:!97ODME3)=ZK?7$9PCS_*BCZ[_9%_
M8%\/>'](TKXB_'+1H==\4W\$=]I7@/5;>.;1?#4$P8P/K]E*7AUC6WA:.5[.
M]C-EI,CF%[:XU&%;FWXC]KK_`(+??L,_LA:_JGP]D\0:_P#&7XDZ$U]I^J>"
M_@O8:5K5EX9U>Q;[.-(\4>+=4U;1?"VEW27BRVFHZ?I%]K^NZ(]K<IJ>AP7`
MM[>Y_+^%O"SQA\:JT,;Q#G.?Y)A,="-?!<&\(1GAJ^&P52SI5,TQ7P4)2C;F
M^O?6)IRM-X=WH+Y+!Y%Q-Q.EC,ZS/%Y5AJRYZ&4Y7)T*D*4K.#Q%5_#.UKJH
MJL];/V7P'E#_`+.?_!1RWMUO4\6?$6:XY?[!'\=F:[4@,0&^T>+X[%F.T+M6
M[D&73H-VWF_^&@/VZ_V;+BW_`.$_'BRXT=[DQB'XEZ0WB70[V9?O6UOXLA=K
MEGV`D06/B1<)B41$$,?D3P]_P=,>![KQ%:VOBS]C7Q9HWA)[MTO-:\/_`!HT
M?Q/XB@LMY"7%KX7U+X<^$M-N[IH\,UG+XOLH4;,8OG4"0_M?^R)_P4G_`&+_
M`/@H)INI^&?A9XPAG\52Z;>-K_P7^)^D6>@^.6T4QK%?3'P[<W>J:-XITCR9
ME34KGPQJWB&PLTF2'5);9Y4C;[//_HA<9\&X-YME>?\`B/PWB*,5-9A7S.CG
M.71DK<KQ]+`.FJ=.4FHR=:K&#O:,)/W7VU?#^MA8^VRW/L^P>(BDXU*N+^M4
M;_\`3RE%4FT]%*\K6TL]2M\,O^"DWP<\2^$M4U/XA0ZAX"\5:'8/=W&A0PSZ
M[:>(&60Q10^%;Z"&)KB[G)@\RRU6'3?LCS,QNKBQM+K48_D/XD_\%&?C;\1=
M</ASX(^'O^$1L[RY:TTE;324\7^/=7+S,ENR6[VM[IUI-<PF+_B76&EW]Q;3
MM(L>JW0\MU]L^/'_``36L_$?C?1=:^"^H:=X2\.:[JHC\8Z)J3326?ABWD=Y
M;G6?#$"YDNH&0-''X<DGMXX;QX!:7MIILDBZ;]I>!/A3\`?V0OAWJ_B*2X\-
M^"M%T'1I+_QS\4O&NHZ;IMR]A9*)[N_\0^)M2>VM=/TV)E\U+&.6TTRV;!AM
MA.[/)^:87(_'_BW&/A7.L\P_#6699..'Q/$F28?_`(4N)?:N+HO`^RG":G*F
MU"K[&.`C"HW&K3JU/W1YM/!<>YI4EEF.Q]++,)A;0JYG@J:^LYE>THNCRRBX
M^YI-P6'4974E.2<#\I-)^$O_``4>\>$:B^M?%W2H;C,IEUOXHR^$]AD.X)_8
MQ\265_;@9.(ETI$C"[-J$*IGOOA1_P`%(/`,AU)-9^+.K06[+,)M(^)H\8"1
MD^;:=%;Q'?W]ROR_-$^DO#)N"E9&9EJO\:_^#C;]@7X8ZOJ^@>!;7XM_'6_T
MUF@M]9\`^%-*TGP3?7D?$L2>(/'/B#PSJTEI')NC&IZ9X8U2RN2@EL9+RTDC
MN7XWX6_\'+/[#OB^^T[3/B)X%^.GPBGO;X6]UKFH>&?#WC/PAI5K))LCOKV]
M\)^);KQ=+'%'^]NH=/\``]Y-$H*VXO6K]3I?0QXFE@?[3AB_%GZRHJJLP>:Q
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M'M/U%-0\`^!/$VC6RRZKX7UNS&GW%]!J,0L1/+9QVMS9S7'SF1^#?B)FV8K)
M\=Q]Q1Q!EV%4O[/R_*,-BO[9Q-*"YZOU]T?;5)N@E;GFL6E%.5Z,5[-+#<+9
MW.I[#'<2X_%8*EI0IT4Z>)J1T_WFI>5Y1>B;=6_]Q>Z5?#/PU_:4LHXIM5U?
MQ)*X(9[>3QXUS,,'HV[6&MVS@DA9V'S#))R!]'>#;GQQIK0VGB)M2(+A6.H#
M[4K,/X5O,R9/7(2X(.,[:[SX>^//"?Q5\`^!_B?X#U0Z[X&^(WA'PUX]\&:V
M;'4M+_MCPIXNT:R\0>'=5_LW6+/3]7T_^T-(U"SN_L.JV%CJ-IYWD7UG;7,<
ML*=>0",$`CT(XK[W*^#:&0U%##YAG'M*,G"K2QV)]J^>#Y9QJ0]G1DIJ2:E&
M2T::Y4SZ+"Y13P37LL3C).+5U6K.HG:UTU:/;\=M[BG(!]0#^8I:BFFCMX99
MY6V0P1232M@MMCB0N[;5!8[54G"@DXP`3Q7P+^SC_P`%1OV%OVM_B.GPC_9[
M^.!\?_$*70]4\21Z`WPS^,'A0-HNBFV&IWG]K>-?`'AO1!]F^UV_^CG4A=S>
M9_H\$NR3;]SALLS+&8?%XO!X#&XO"Y?"%3'XG#82O7P^"ISY^2IBZU*G*GAH
M3]G4<95I0C)4YM-J$K>NHR:;46U'5M)M)>?8^_Z***XB0HKG/&'C#PK\/O"W
MB#QQXX\0Z/X3\'^%-(OM>\2^)?$%_;:7HNAZ-IEN]U?ZEJ>H7<D5M:6EK;QO
M+--+(JJJ]<D`_P`Z?Q\_X.8_V5O`&L7VA_`SX1_$KX]R:=>WEG)XDO\`4-.^
M%/@G5([>18[>_P##^H:I8>*?%UW:76)G!UCP-H,J1K`ZQ3><XA^BR#A/B/BB
MI4I9!E&,S)T;*M4HPC&A1<E>,:N)K2IX>G.23<83JJ<DFXQ=C2%*=3X(MVW?
M1?-_\.?TGT5_/=^R/_P</_LZ_M*?$GX>?!KQ7\%?BW\*_B/\3O%_A[P1X773
M)=#^)7@LZYXDO;?2["+4M?LI?#'B2SMSJ-S%$]VO@:YM+>UWW]]-9012^65G
MGG"_$'#6*A@L\RO$Y=B:M)5J5.LH252DY.'M*=2C.I2G'G3BW";M)-.S3"5*
MI%VE!I_\&W3S/PA_X.-OC3XT\??M_P!Y\)=9U"ZB\#_`KP%X-TKP;H\A9=-B
MU'Q_X=T;QQXL\211B,L][JTFH:/HU[<)YF^T\*:;`BA[=]W]#/[/'_!!7_@F
MEHOP9\%P>+?`/_#0VO:YX5T34]5^+]U\1OB#I-IXPFU32K>Z;7/"6G^!?&VE
M:#HGAJ_:Y>]\/1Z<;V]CTV>T^V:]K,T*7[^'?\%O/^"/OCC]L75]+_:?_9J3
M3[_XV>'/"\'A?QS\-=0N[;2Q\3/#NB_:[G0=4\-:Q>SV^FV7C;14N)M'DTW6
M);;3O$>C/IRQ:OI-]H$5GXB_GL_9Y_X*;_\`!2+_`()@:S;_``/\46OB*/PK
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MIG?\$V?^"K'P._X*,^'-5L?#EA<?#3XV>$-.35?&_P`'=>U6UU2^AT=[N.R7
MQ3X-UJ*WT_\`X2_PG'=W%C8ZEJ"Z5I=_H.IW]C8ZUI=I'J>AWNL?J37X%F>9
M<:</\45L;FN,S3`<58-*C5Q>(JN6/C%X586+5=N:JTZF$:IPK0E.%6D^:,Y<
MW,_VG+\OX2SWAVEA,NPN`Q?#F*E[:&%H0<,)*:Q"Q#4J47"5.I#$+FG2DHRI
MS7*XQM8_C5_X*7_\$)?V2_V,OV)_C-^TE\,OB1^T5X@\<?#I_ARNBZ3X[\5?
M#/4?"MW_`,)A\6/`O@34O[5LO#_PE\,ZO-Y&D>)[^XL?LFN6/EZC#9RS_:;:
M.:TG^1/^",7_``2C_9[_`."BW@/XY>*?C5XU^,OA6_\`AEXM\(Z#H4/PNU[P
M1HUG>6>OZ-JVHWDNK1^+/A]XUGGN8IK"%;9[.XL(DB:02PS,5=/Z9O\`@O3_
M`,HH_P!J3_KK\#?_`%HWX1U^:?\`P:S?\D@_:W_[*3\-/_48\1U^VY7QMQ96
M\%N),^JY]F$\XPO%6&P>'S&5;_:J.%G'(W*A"?+I3D\16NO^GDNY^19APAPU
M2\5\BR2GD^$AE6(X?KXJO@5&?L:N(@LTY:LESWYE["ELTO<6A]^_LD?\$(_V
M2_V-?VA/A]^TG\,OB3^T7K_C?X;_`/"5_P!B:3X[\4_#34?"MW_PE_@GQ)X#
MU+^U;+P_\)?#&KS>1I'BC4+FQ^QZW8^7J4-G-<?:;6.:SN/2?^"X7Q(\0?#'
M_@F-^TKJWA75M3T/7O$-AX$\!0ZEI4[6T\>D^./B3X0\.^+;.:>*>">*TUCP
M;>^(-%N/),C2IJ/D/'Y$LKI^LOY]:_%3_@X*'_&KWXT^_B_X-?I\5/"G_P!?
M\Z_).',WS/BGQ`X0K\0XVOF];^V\EPKGC)*JWAJ>8PJQP[NDG2YZE1\K5GSR
M3T9^GYYE.7<.<%<3T,CPE/+:7]E9IB>3"\T$L1+`NFZR;DW&?)3IJZ:MRJVQ
M_-W_`,$??^".O@#_`(*)_#?XF_%WXJ?%;QIX&\*>"O'?_"N-&T#X?V.@KK>I
MZY;^'=#\3:EJNH:QXBLM9L[;3;>S\0Z9:VUC!HLD]W.]U,VH6J6R17'['?\`
M$+W^Q]_T7S]I3_P.^%X'Y_\`"N3S[9K\`/\`@G;_`,%C?BO_`,$ZOA+XQ^$G
M@/X1?#[X@Z7XQ^(U[\1KO5O%NJ^(K&_M+Z]\,^&?#+Z=;Q:/-%;M:1P>&;>Y
M620&8S74RD[$05^M/[-?_!Q[\?/CA^T9\`?@MK/[//PBT72/B_\`&OX5?"[5
M=9TW7?&,VHZ3IWQ`\=:#X3OM3L(KFZ:VEO;"VU>6[M8[A6@>>*-9E,98'^@>
M.<)XW0SO/LQR/,98;AS#NIB,%"EC,HIJG@</AX3G+V%5/$.?N5)R4[U)2YK:
M.*/Q3A#%>$;RG)L%G&!6(SVLH4<7*IA<QJ<^+KU^2$?:TFJ*BN>G%.-HQCN[
MW9_29^Q;^R5X)_8A_9\\*?LZ_#SQ'XJ\5^%?"6I^*=4L=;\9R:3+X@N9O%GB
M+4?$M['=OH>F:/IQCM[O4IH+7R;")A;1Q"9I90\K^V?%;QK;?#7X8?$;XC7@
M5K3P#X#\7^-+I&(4/;>%O#^H:Y.I8\*ICL6!)X`.3Q7?U^;_`/P5X^)5W\*/
M^";7[7?BFQ_X^M3^%-Y\/(SN53&GQ9U?2OA=<SQLRMMEMK3QA<7$14+*)(E\
MF2.78Z_RQ@_K?$?$>$6,JRQ.-SO.</'$UYVYZ^(S#&PC5J2Y8J/-4J592?+%
M*[T70_HO%_5LAR#%?5:<</A,IRJN\/2C?DI4<'A9NE3CS-OEA&G&*NV[+5G^
M;/X<\>>*/"_C[0OB=I6I2IXT\.^,-+\>:=K$WSS+XHTG6H/$-GJ4NTH7E&K6
M\=T^"F]@V",\?ZKOP$^+&C?'CX)_";XU>'O(71OBK\.O!_CVSMX+I+U;`>)]
M"L=6ETN2XC"A[G2I[J73;Q62.6*\M)X9XH9HWB7_`#TOV;_V+?\`A=/_``2Z
M_;C_`&B].TZ]O/%OP2^*WP:UWP\=/L1=W$OAKP5HGBN/XJ:?))MWVVD6WA;X
MJV/C7698MS1GP+ITDWEVJS/7],W_``;<?M$)\2OV(/$/P6U.XLDUG]FSXAZO
MI5I#'+FZ?P'\2)]0\>:#J.H+(Y\MG\3W'C[3('39"UGH\``\V.=F_I?QXPV"
MSW)'F>7Q;Q7!.>K(,S22O&AF6!P6)IS5M72A7J82C"ZTJU*\5\,F?S_X-XG%
M9-F_U#'-1PW%>4/.,`W>TJN!Q6)HSCKHJDJ4,1.5M90A2D[WBC\Z/^#H']HD
MZW\3O@!^RYI&H6LNG^!O#.I_&#QI:VUPD\B^)O&%U<^&_"5EJ,2;OL5YI'A[
M1-;U*"!RL\MCXPM[F2,026DDG0_\&LWQ&>W\7_M=?"2XG+1:MX<^%_Q%TJV+
M.5ADT#4_%7AK7YXTY0&Y3Q+X;CF8X8BTA`RH;;\2_!30;3_@J[_P7'\1^+-<
ML?\`A(OA-/\`%3Q+\1=8?2H%GTNX^"WP-LH-!^&Z:N+@S1G3/%Z^'_AYX;UZ
M4?+=7'BNY^S+!]IA6+?_`.""&O7_`,`?^"KWB+X)ZCOEE\5^$_CG\#]1+L%6
M+4_`.H)XV6]=!\IG$OPONK)2OW!J,P&%9J]+,LJP>!\(<UX&A'_A8R?A/+.*
M<QIZ+EK8O'ULQKI_:=2@\'6A)-)J$\/>W-8\_`9EBL9XG9=Q=*3_`+,S3B;&
MY!@IWT='#X.C@Z3O\/)4CB:,]&[R557T/[I?'_BJ#P+X%\8^-+J(3P>$O"^O
M>))H/,\KSX]$TNZU)X!(0VPS"V,8;:Q4L#M.,5^$?["?P[F^.O[1VK?$/QLH
MU>V\(2W?Q#UI[F-I8]3\9:QJ<KZ()OWGR"/4WO->3<TRM+HT5L\,L,SM'^J'
M[=M_=:=^RI\69[25HI);+PW8.P_BMM4\9>'M.O(\Y'$UI=30MV`<G!KY?_X)
M4Z1:1>`?BKKJ(HO[_P`7Z/I$\P4"1K32M&-Y:HS]66.;6KQE4C"M([<ES7^6
M''^'7$GC5X9\-8Q*KE>6X',>):N&GK2KXJA[>=%U8-VFJ<\!1LFFG&=6&L9S
M1^T9]368\9\-9;67-A<-0Q.9RIO6-2M3YW3<H[/DEAX;WTE)6LV?`_\`P<%?
M\%'O%G[.7@CPW^R;\%=<O/#?Q/\`C+X:N/$GQ"\7:9+);ZMX4^$MQ?ZAH-MI
M6@WL3J]CK?CW5-+UK3[G4H6%WI/A[1]1CMUCN]=T_4;#\U_^"5'_``0=/[3O
M@70OVC_VM-5\4>#?A-XI@CU3X:_#3PS-!I/C#X@Z',2UMXP\0ZW<PWDWACPA
MJ>TMH5A9V`U_Q/ITJ:[;:EH6D/I-UKWRA_P5'T0_&O\`X+7_`!"^'/BG4K]-
M'\6_&[]GWX522B9WETGPYJ_A;X6^&9UTQ)&$=LJ17]YJ$44?EQO?7,]R^9KB
M:1_]!71=&TOP]H^D:!H=C;:7HNAZ98Z/I&F64:PV>GZ7IMK%9:?86L*C;%;6
M=K#%!;Q+A8XHU51@5_HMG>=U_#/P\X0RGAB2P6<<7Y<L]SG.*4(K&*E6I4)T
M\/0JM/D<?K'U>G4B^:C2P\ITU3JU_:'ZA.;P]&E&GI*HE*4UO?1Z??9=EYGY
M(ZW_`,$'/^"7>K^&Y/#]M^SK=Z!<&V\FV\2Z+\5_BZOB2SG$;1B_CN=4\<:I
MIUW<KO:3R=5TO4-.>389+%TBB1/R0@_X-O?BE\/OVP_`WB3X+?M(ZEX0_9ZT
M;4H_'%O\38918?'_`.'NIZ)J7VC3_">@6VF0VNB:UK]V%LSIGC\-HNF6$;:I
M=ZGX1FFTO3]&\4?UXT5^899XG<<Y7#&4Z?$&.QE+'8>MAZU'-:DLUI)5H<CJ
MTH8YUU3JP6L>7]VWI4IU(WB<\<15C>TFTU:TM5ZKS_IW*MK`UM9VUM-=3WLE
MO;PPR7MUY`NKMXHU1KFX^S06UL)YV4R2_9[:W@\QV$,$,>V-?X`_^"F'[;WQ
MQ_X*D?M?Z?\`LS?`JYU36/@UIWQ-@^'GP.^'6C7'V#3OB!XLCNY-!F^*?BV9
M[A;6\DU"X?4KO0]2U=[?2O!/@(BX\C3;RZ\6:IJG]M/[;'BG6O`_[''[5GC'
MPW?76F>(?"_[.?QIU[0M3LG\N\TW6-+^'7B*\TW4+20!C'<V5Y%#=0/@[)8E
M;M7^<#^PW^UUK7[#O[06A?M#^&O`/ACXB^)/#6@^)]&T/2/%EWJ=EINGW7BG
M3)-$O-8BFTETN_MD.CW>IZ?$F\1F+49BW*K7Z;X$\/RQ-'BGBC"X'#YEGF48
M:&&X>PN*E3A0CF6(HUJOM9SJ2C3IRO"A2C5YHNG3G7Y9)R36^#@K3J)<TXV4
M$]DVM_RU[7/ZZ/V6O^#;_P#9$^'_`(-T:X_:?O?%'Q\^)5U:07'B2TTOQ3XB
M^'_PVTJ^ECBDFTKPY:>$KS0O%^H6UA)YMI_;>L>(H9=81%OUT'P^9?[.@^FM
M&_X(*_\`!.7PM\6?AY\6/"'PV\8>'9OAWXGT_P`5VW@63XA>(/%G@#Q+J&DL
MUSI<'BK3/'TOBW6M1TVTU-;34VTZU\0:?::A+9166JQ7VE3WUA=?A_\`\11'
M[1W_`$;-\%/_``HO'/\`\EU_0=_P26_;Z\;?\%$?V?\`QW\8?'G@3PM\/M5\
M)?&/6?AI:Z1X2O=6OM/N]/TSP5X#\4QZE/+K$DMRMY)<^+KFU>.-A`L-I`R@
M.TA/E\7X/QKR+"8OB#B+.<RP^#KS6$K_`%;/:$L.OKMX*C3P&#Q'LJ=.2;BO
M9T8J"ZIZDU%BH)U)R:76TEULK67K;Y>A^I2@```8`'`]!7\+7_!SE_R?E\)/
M^S1_`G_JX_CS7]TP]SGWK^%G_@YR_P"3\OA)_P!FC^!/_5Q_'FO/\!/^3CY=
M_P!B_-?_`%#F3@_XR_PR/ZZ?^"?/_)A/[$7_`&:)^S;_`.J;\&5]>U\A?\$^
M?^3"?V(O^S1/V;?_`%3?@ROKVORO.?\`D<9K_P!C+'?^I54YY_'+_%+\V9NL
M_P#('U7_`+!M]_Z2RU_`[_P;C_\`*1S3_P#LA_Q1_GX<K^^+6?\`D#ZK_P!@
MV^_])9:_@=_X-Q_^4CFG_P#9#_BC_/PY7[#X8_\`)O?&/_L297_Z;SLZJ'\#
M$_X?TD?WZ4445^&'&?S+?\'./QG\8>#?V;/@9\&=!>_LO#?QH^(WB#5?&]_9
MR3PV]_IOPNTW1+_1_"FIF.58I[+5->\56/B5+2:&4/?>"[.Y1HFLR)/$?^"#
M/_!-_P#8L^/'[+VI?M"?&7P!X>^-_P`2=2^(?BSP9<Z)XON;C4_#7P^T[P_'
MIC6>E)X3BN8M*GUS6;2\MO$5QJ^MVU_=Q:=J6F0:.--B%])J7[O?\%(?V%O#
M'_!03]FO6/@KJVM#PGXJTO6K'QS\,_&+6IO8/#OCG1[+4]/M&U2T0I/>:#JV
MEZQJFBZQ;6\J3);WR:C;++>Z=:1M_#IJG@7_`(*<_P#!&_XGWNO64/Q%^#,5
M[J5OITWC'P[&?%GP*^*,6G^?<:=;W]S+::AX&\3C[)<74]CIGB2RM?%>AP7E
MVXL-#OVN/+_I?@&M1XF\-*G!/#_$=+AGBVCFM;&U(SQ%3!SSFC4J3G"$,11<
M:[IRI.C1J^P]K5IO"4U4I.C6U[Z/[RA[.%3DJ*3?:Z;OZ^5UJK=C^U_PS_P2
M2_8,\!?'CX;?M&_#3X)67PU^(OPPUF\UW1HO!>LZQI_@_4[RYT/5=$MO[7\%
MW=W?^'D_LMM5;5]-N-"LM#OTUBRT^>ZO+NT@>RF*_,+_`()F?\'`&B_M&^-_
M"7[/_P"UEX7T/X<_%3Q?J%EX=\#?$SP?]HMOASXS\0W]Q-;Z9X?\0:)JE[>Z
MCX)\0:K*VGZ?I%W;:EK>@Z]K-U+;NOA3?IUG>E?CG&63<9Y5F=/`<6K,L3C,
M-AHPPE;%8BMF,)X)U:DH/"8ISJJ=#VLJC4.92IR;A.$)>ZN:K"LI*-3FDTM'
MK)6OT?K^/F?TF6^NZ)=:OJ.@6NKZ7<:[I-O87FK:-!J%I-JVFVFJ?:?[,NM0
MTZ.9KRRM]1^QW?V&>YABBO/LMS]G:3R)=GSW^UI^SK^SS^TG\%?&7@G]I+PK
MX7UGP#;Z'K&K7'B+7X;.VO\`X?R66E7QD\;^'O$DH6[\+ZOH%G)=W4>KV=U;
M[+;[5;7OVC3KF\M9_P"<;_@J?_P2Z_X*8_%3]M?QE^V!^ROXCL-8AU/3O!NG
M>`[;X>?%:3X2_%/P/8>%_"^G:+-I_P!OU[4_">F`SZM!JNLI>Z3XR9[E]8F4
MV%D1Y%?GQKO[!_\`P<#?M&:7-\*_BG)^T'K7@6ZGBMM;T_XJ_M(^'/\`A!YT
MMID>.XUFPN?B1?/XGMK:;9/$;;2]?E+QB>UBD:#?']EP_P"'^3UZ&3Y[A?%#
MAO**BHX3&8VG6Q7U+-<IQ/+"=>C1B\1"=6I1ES1IU']74Y*R4TN:7Y!G?&V:
MTJN:9/B?#S.\RA*IB<-A)TZ#Q.7YA1NX4:M:2H2C3A5A:4XQ=9Q76+V^9/\`
M@AAJ_BK2/^"HW[-=OX2NK\1ZU=?$G1?$<%H]Q#!J?A)_A9XVO]3BU2&,.LMC
M;2:=9:S'!=*8H]3TS39]T5Q;P31_Z.M?A;_P2&_X(Z:;_P`$^_[:^,'Q7\2Z
M/X__`&D/%^@-X:-QX;%^/!GPV\*7LUC?:KX>\.3:@EI=>(M8UF_T^REUGQ5?
M:7IC16EG;Z-HFGV=JVLW_B']TJX/&3BK*>+.+HXO)JGUG!8#+<-EOU[DE#Z]
M6H5<15J5X*48R=).O[*G*27.J;G'W)1.[PJX<S+AOAF6'S6'L,3C<?6QZP?,
MI/"4ZM*A2A2FU*454DJ/M)QB_=YU&5IJ2/R`_P""]/\`RBC_`&I/^NOP-_\`
M6C?A'7YI_P#!K-_R2#]K?_LI/PT_]1?Q'7[%_P#!6_X"_%C]IO\`X)]?'SX(
M?`_PH?&_Q0\:2?"EO#/A@:YX<\.'4QX;^-7PY\6ZU_Q.?%NL:#X>L_L7A[0M
M5U#_`(F&K6GVC[)]EM//OI[:VF^'?^"!?[$W[3O[%GPW_:*T']IGX9'X::MX
MZ\;^!]7\*VA\8_#_`,8?VKIVCZ#K5EJ-QY_@'Q5XIMK+[/<W=O'Y6HS6D\OF
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MZ).;2;>R=S\)_P#@V(M_#.K?L?\`QXT^]M=%U+6+#]I/4;R>TN[:RN[^TTW4
M?A?\-X-/N)(YHY)H;2\NM,U2*U=@L4TUE>+&2T,F/Z5H?#7AVWECG@T'189H
MI%EAFBTNQCEBE1@R212)`KQNC`,C*0RL`0017\!]E_P15_X++?`#QIXB@^!W
MA/7H5D1])E^(7P3_`&DO`7P]L/%6DQ7(FA7&K_$CX>>,&L'EAANQ8ZWH5IY<
MRQL8?-B##KC_`,$Z_P#@X=/_`"T_:8_\3C\!_P#T0]?NG%O!/"_%/$6:\087
MQ5X2PF'S>O'%PPN)QN&5:BIT:494YK^T*;T<793ITYI6C."DF?C?#/%N?<.Y
M'EV2XGPXXCQ5?+*3PTL30P=5TZSC5E)5(OZG/I)*\9SBW:49<K2/[W:_GN_X
M.4_B;J/@O_@G_H?@C3I=B?&'X[^!?">N1;E'G>'?#>D^*/B))P59F\OQ+X1\
M+-A3'@$EI,#RY/OO_@E5\,OVF/A!^Q7\.?`G[79\5'XZ:9KWQ#N?$Q\:>/\`
M3OB;XA_L[4_'&N7_`(:^U^,=*\2^+K+4(_[`N-/^RPQZ[=-86WE64D=L\#6\
M?YU?\%^/V-/VROVT]._9I\'?LO\`PCE^)'AKP->_$OQ-X_N/^$[^&/@^*SUW
M58/!VE^#X4A\>^-O"MS>R1Z?;^+7EDT^VO((UNX5EGAD(CD_->",)E65^)V5
M8?'9QELLKR?/,1.6=2Q-"AEN(AE?MZN&Q5+$5:JI*EBJU"BZ#567-[2'*Y7N
M??\`%V*S',O#W,*^$RO'QS'-,IP\5E4:%6MCJ$L>Z,*^'J4:=/VKG0IU:D:O
M[N+CRR;2L=+_`,$$?V?_``M?_P#!*&[T3Q+:&^T+]I[Q7\<[[QC:+NBDN=$U
M1I/@G?6"RR>:-LVB>!V:-DB\F.2[D/E-+YKR_P`L7P(_:0^(G_!+KXN?MX_!
M.2QO=2U_Q5\-?C#^S!)<PRW&CKH_CS2O$DFA^%OB9%`=TD\.D6<?B"^T>)7"
MSIKUK=1736V[S_[X?^"?WP%U#]F+]BW]FWX':WI2:%XH\#_"SP['XXT>.YL+
MV/3?B%K\3^*?B%9K?:5=W^F:@(/&VMZ]'_:&GWMU8WVW[7:SR03(Q_FS_P""
MSO\`P1X_:U_:!_;0UKX]?LH_"-_B7X7^*7@GPCJ/CN7_`(3WX5>#1H/Q"\.6
M+>#;JR@LO'/C3PI?WEKJ'ACP_P"%]7:\MX+R)M2O-3C>Y0JD2_HW`W%V0X_C
M?C[+^)<;@J?#O%6,Q..IXC&XJE0P;KY;F4J^7VKU91I1]KAI-P;FE4]C3I^^
MY11\'QAPQG&"X1X*QV183&3SOA["X?!U*6%P]2MB_8X_!*EB[T:<95&X5[J<
M>5N'M:DG9*37I?\`P:^?L[IIG@3]H7]J75[*X2]\5Z_I7P4\&7%Q;R0(-"\,
MVUGXM\:75C*Q'VVUU?6M8\+6#S(GDP7GA2[MUEDF%S'!^;7B1Y?V0O\`@XF^
MTZ6R-9ZC^VAHEW<F1S%#:>'/VJ3I\WB)8]J#$6C:)\8-32VA*A6-A%%YFTB:
MO['/^">_[-LG[)/[&7[/WP$OX&MO$?@SP)97?CB!KFSO?)^(GBRZNO&/C^WA
MO=/EGL[NSLO%^O:Q8Z=<6T]Q#)IMK:;+B=<2O_/3_P`%>/\`@EO^VM\7?^"A
M&C?M4?LA?!R3XB:7?^%_A-XLUS7/^%C?"KP9_9GQ3^'-]<:)!I\=CXX\<^&-
M6D2'PQX3\#:@-1L[&:R::\FABN6N;6XCC7#O&F6YWXB^(%;-,QP6!RCB3(\W
MRC!XC'8BEA\&Z6&]AA<M3K5I0I1]MA:=2HHN7O3J.,;R:N\]X4Q^4\"<%4LO
MP&+Q>99'F^6YEBZ&$H5:V)]KB'/$8Y^RI*51^SKRA3;M[L8IR:LVOZ9_VHO"
M*>.OV>OBYX=,33S2^"=7U2PA1#(\VJ>'H?\`A(=(C5`&8F34]+M%&U2XSE`7
M`K\Z/^"5/C2%+SXK_#V>91-<0:'XQTN`D;I([9Y]&UN15X+"(W&@#*@@>8=Q
M!*Y_8:U,MU8V[W=J]I-<6L3W-E.\$TEK++"K36LDEO)+;2O`[-"[PRR0.58Q
MR/&58_SQ^.M-\4?L-?M8IKVBV3R>&DU.XUWPY;DB*T\0?#S7Y)HM1T`-%*Z)
M=:7&]WH\<EPB-!J6FV&L_8C;/:QR_P"='B[*IPAQOX?>)DJ<ZF599B,3P]Q#
M4I1=3ZM@<Q52%'$M1O>$/;XIWT4JD*-)-NLC[CBN4LJSKA[B9PD\+AY5,!F+
M47>E0Q46H5)*S:4?:56[V]Z,8;S1^+W_``<*_L\>+_@3^WE9?M):#+J\'AKX
M_:/X5\9Z!XD@A\B#P[\3/AII>B^$=:T*PO8F=OMMI8^'_"7C2">?RI#-XEN(
M;9'CTQV7^M;_`()W?MU?#;]O/]GGPO\`$SPIJ^GQ_$#2-+TC1OC+X#618M7\
M#>/EL]FHPRV3$2/X=UVXMKK5?".L1![34])?R&>#6-.UG2]-UOVC/V>OV?/^
M"EO[+LO@;Q>1JW@SQC;0>(O!/C#34@7Q+X`\96$=U;:?XCT9Y0QL];T6YEOM
M)UG2IR(=0L9=7\/ZBIM;R>OXO/B]_P`$S?\`@J!_P3/^*MY\0_@5:?%'Q-HN
MF+J@T/XX_LV0Z_JC7OAB&5)YX?'?A#0/[1U_PY:M;):76N:-XITW4_"#RQRI
M::WKT&GS7B?Z#Y%F'"_B]P+P]D.)S[`Y1Q-P]AH4^'LRQ-2']FYSE5:G26'I
MPK<RC/GH4\-"2A)UXRH0Q%.G7A4JTU^G4:M#'X>C*%6#O"$J5524H5*<DG&<
M9)^]&4;/2_=73/\`0?R!U_S^/2O)M1^//P7TCXNZ%\`M3^)_@JP^-/B?P[>>
M+?#_`,,;KQ!I\/C+5_#M@\ZW.J6.BO,+N:$"SOYH8U3S[JUTO5[RUBFM-'U.
M:T_@6A_X+&_\%?\`XF+#\*?#WQH\=:WXEU21M(BT[P)\$OAW'\1M0GC\R"2R
MLG\+_#9/$<&HJY56FT:.TU99H5_TA7,_F_5?["G_``10_;9_::^,VE?M"_M<
MZY\3_@/X?@\5VGC76O%?B[7=7MOVE_'&OZ?J-M?";1([^YE\3^"M3DF@?/C?
MQ>]GJVD3):WFBZ!K@_>6O!7\'<-D&!QN8<9<9Y%E=&GAZSP%'+*LLRQ>,Q*C
M^Y4</4CA:E2#F_?IT(U*C6KG2CS5(OZJH)NK5C%6TMJV_G^GY;_VL_%?X>:+
M\7?A=\1_A3XD:X3P]\3/`GBWP!KKVCA+N/1_&&@W_A_4I+60\)<QV>H3/;O_
M``RJC=J_SAOV2#\+OV-O^"@5AX$_;E^$WAGQG\.O!_C+Q1\(OC#X;\=^%K/Q
M/I?AMKMYM%M/'T&CZE9WRWEIX=U--,\3+>6%O<7FH>%&OGT874E];)/_`*2>
MHZ_X:\(0:!8ZWK^GZ1_:M_8^&M`.O:PJ76LZO-$XLM,MKK4[DW6JZM=QV\C(
MAEN+Z\='D8RRLS'\7/\`@JS_`,$9O`G[>H;XP?"W5-&^%O[3FEZ;'93Z_?VD
MW_"'_%?3--L)(-'T7X@)IT4E[I^MZ<8[*PT;Q]86FJ:A9:'$="U;1]>T^T\/
M?\(WY7A/QQD^18GB#AO/<75P^3<182GA,7C,'5DL7E.*=.K'#8J2H-UZ$:M+
M$2O42<J;A0JJ,J:J-9X7$4XRJ4I26ME/EE[U-M7CS).\>:+NKKL]C[-\.?\`
M!/+_`()K>,-`T7Q5X4_9(_95\2>&?$FEV&N>'_$&A?##P#JNC:WHVJ6T=YIN
MJZ5J5CIT]G?Z??VDT5S9WEK-+;W$$L<L4CHZL?J/X0?`OX,?L_\`AZ_\(_!#
MX7>!OA-X7U76I_$>I:!X!\-Z7X7TB_UZYL=/TRXUBZL=*M[:"?49M/TK3+*2
M[D0S/;6%I$7,<,8'\'V@>"_^"Y7_``33;5_!GP\T#]I7PCX)T:\NKYQX&\)Q
M_'7X+)]H8R2ZWIT0T'XA>`M*&I!$N+J2:QTG4F8I'J]K!>(T">N?!/\`:B_X
M+^?&+XT?"[XAZ5H7[4?Q0L_"?C+2[R7PO??#9?A%\%O%]M#<&WU;PMXXOM-\
M*_#_`.&_]FZG82W=A=W^O7(DT)YHM8M)[+4;"RNX/H\R\+,ZQ>'Q.)H^)/#^
M:Y!&%3$8?$XW/ZZ5;DBYT(5:-25;"4JLO=CSO$RC3D[W2T6LL/-W:KQE"UTY
M2>JZ7UMVUV_(_N]K^%G_`(.<O^3\OA)_V:/X$_\`5Q_'FO[E=)NKV]TK3+S4
MM-ET;4;RPL[F^T>>XM;N?2[R>WCENM.FNK&6XL;F6QF9[:2XLYYK29XC);RR
M0NCM^)'_``6?_P""56N?\%`O"'@?XA?!N_\`#FC_`+0/PGL]2T?3[7Q)*=-T
MGXB^!M4NHM0D\)7^O16]U)I6J:!J8O=6\(7-U"VD&ZUO7]/U22QBU9-8TOX[
MPCS[+>&N.\LS#-\1'"X%T\;@ZN*E[U&A/%8>=*G4JRAS6H^TY8RJ*\8*7M)-
M4XRDLL-.,*R<G96:OT5S[T_X)P:_HGB+_@G_`/L57NA:K8:M:6G[+7P(T*YN
M+"YBN88-9\-?#3PWX=\0:9*\3,J7NCZ[I>HZ3J-NQ$EK?V5S;2JLL3J/M/(]
M1^8K_.RMO^"'O_!7+2U:TTW]G'5;:V21]JV'Q^^`%K;2'<<RI$OQB@8"3[^9
M(DD.?G56R!8_X<G?\%@?^C>?$7_B0WP"_P#GSU]KF'A9P;C,?C<72\7N$J=/
M%8O$8FG3J5,OG.G"O5E5C"<XYW!3E!347)0@I/50C?E6LL/2<FUB(:N_1[M=
M>?S_`"\[?Z&FL\Z/JO\`V#;[_P!)9:_S_?\`@WE\5>'O#'_!2+PA!X@U>PTA
M_%'PM^)?AC0?[0NH;1=3U^YL-.U2VTFU>=XUEOKJSTB_DMK9"9KAX#%"CR,J
MG^X?]D7P+XM^'/[)'[,7PR^(^F2:7X[\"?LZ?!?P-X\T:?4+#6)-.\6^&/AK
MX;T#Q1ILVK:5>ZCI6J26>LV-]:R:AINI7]A>M&;FSO;JVECG?^-?]K[_`(-Z
M/VRO`GQF\3W/[)OA#3OC1\'-8UV^UCP/+'\0O`?@WQEX-TJ[N'N[3P[XIM_'
M_B/P?:WM]H9?^SK76_#UYJ$6KVUO;ZG/::/=7$^FVG%X58WARE@O$/A#.L_P
M>41XCP-#!X'-L5.G3P4OJ;S*C.JJE2K"AS2^MT:U*E.O!5J:G&%7FLQ8=PM6
MI2FH\ZLI.R3M=:7=KN]TK_>?W:9'J/S%&1ZC\Z_SNO\`AR=_P6!_Z-Y\1?\`
MB0WP"_\`GSU^M7_!%O\`X)N_\%`OV6?VS?\`A:/[2GPFU?P9\-_^%3^.O#G]
MLWOQ:^%?C2'^W]7N_#LFEVG]C>#_`(B^*-7WSQV-X5N_[,^RP>61/<1&2,/Y
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MWB>;PGJOB?Q!?Z7I.F>#]8\/ZG/9/H?V_P`-V8\66075]7T)8T\3/)#=3?O%
MB_G[@_9V_P"#BOPS"OPULKW]LJ"P6(:7;QV'[0=IJ.D6MK"%MH[:R\:6OQ-N
M]-T^RCCD6.!K7Q!;6L=NN(F6&W;RO-X:X`ROB'*,+F4./N&\FS%U:ZQ65YMB
M%@\1A(TJTH4:M.JZJE5]K3C&LE&E&,%.*]LY7C%4Z$9PC+VT(RN[QEHU9^J>
MVNUMM3XU_P""N/PC^#'[/_\`P4)^,?@+]FTV&D^#]&O_``IK47AOPU<K-IO@
M/QOJ^A:7K/B'PKH9MVD%E#I&MW#7%MI$+;?#DMT?#\,5LNEK:PE?M#_P3A_X
M-]/BOH_Q;\,_'C]NRX\/6&F>#M>L?%ND_!33M<L?'.M>,?%%C<MJ-M-\2O$%
MA+?>&8O#]IJ4=K>7>CZ5J?B>;Q8XGLM5NM*T])H]7*_9\[\7N&^':>3Y#AYR
MXTJY5E6%PF,SR$X>RQ&)HQC";A6J.I[=S4%5G4ISJPO-1=:I4C,ZI8FG#E@G
M[3EBDY;IM65_GN[7/Z_:,=Z**_D@\P****`"BBB@`HHHH`****`"BBB@`HHH
MH`****`"OGW]HW]GCPE^T7X&D\,:^S:;K>G&:]\)>*+>)9;S0-6>/;N:(L@O
M=*O=D<.K:8\D:W<"H\,UI?V]E?6OT%17G9ME.79[EN,RC-L+2QN7X^C/#XK#
M5E>%2G/S5I1G%VG3J0:G3G&,X2C**:Y\7A,/CL/6PF+I1KX>O!TZM*:O&47^
M*:WC)-2C)*46I)-?SG:%XI_:3_8%\=S:3J.FR)X?U2^=[G2=06[O/`/C:"U^
MSB?4M`U-%A2WU1+22V4WMKY.IV'F6L&M:?/$BV+_`*2?#S_@I/\``+Q3:6J^
M-#X@^&^K.H6[@U/2[O7]&6X9L*MGJ_AZVO;F:WY7_2+_`$G2MC;_`#(UC3SF
M^[?$GA;PWXRTJ\T#Q9H.D^)-$O55+K2M;L+;4K&8#YE+VUW'+'O1P'CD"AXY
M%62-E=58?AG^VY\#?A7\,/$NGIX#\)0>'8M0T^2\NH+;4]<N;=K@R,-T-O?Z
MG=P6J``!8+6.&!?X8QDU_,^;Y%Q[X*X2>)X/XGP6;<(NN_8</<3T,17J9>ZC
M<G3PN)PJ4W3W_AU<+%MWE0E-RF_S;%X#/>#*,JN3YE0Q>4>T]S+LTA4G+#N;
M;Y:-6E:7+N])4DWJX2DW(_5&3]L7]F&&`W+?&'PB8UC\PK%)>37.T@,%6TAL
MWNF<`X,2PF53E2@((KYJ^*?_``4T^$7AVQN;?X8Z5K/Q"UQA)':7EU9W7AGP
MU$=C!;BXGU.&+6[E8Y3&19Q:1`MT@D'V^T/ER-^$-H!+<PQO\R,V".F1@]Q@
MC\"*_8_]AW]G;X*^-]`U#Q-XP\`:3XEU;3[N%+5]:N-4U"P5'CDD99M%N;^3
M1;H%D7_CZT^;Y<H/D9E/CY-XK^*_'N.IY!D\N$.':^)_=RS*-#,L36HKE5YT
M88AXFCSI7Y>>C+7JK7.3!<4\5Y_7C@,&\GR^I--/$^SQ-6<(I*[IJI[2"=KM
M*4'KU73XKUK2/VK/VP+O6_BJWA_Q%XMT_P`-07$MB=+A.F:#ID<,\9GT;P/I
M]Q<*=1U&#`GN+72WU'6)S!&;V>XO9+1)OHSX#_\`!1WQA\/XX/!?QST+4_&%
MAI3+IH\2VF+;QSI@M9)XKB#7;#49(+;7IX'$%OYLD^D:E`MO.]]+JMW+E/VZ
MM+*STZUBL=/M+:QLK2*."UM+."*VMK:%`%2&""%4BBB10`L:*JJ!@`"OG_XX
M_L__``:^)>C:IKGC7X?:#K&N6FE73PZY&EUI.MG[/;R2P1S:QHMSIVI74$,@
MW1VUS=36Z[G`B`DD#?43\'^,.$?:\5<*^(F-J\3SISQ'$4L\I2KY7GDHWF^:
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ME@R>6@F?T_X>_LY?`SPEX8&G:)\,/"D=MK6G16^K'4;`Z]=ZA;OY<K6]UJ&O
M2:E?RP>:%E$+7/EK(D<BJ&CC*_$G[1_PA^'/P]\1:>/!OAF#04OK62YN(;:^
MU66W,PEV@Q6]W?W$%L@`XBMHX8AU"9K]'G/Q>X8P]+B3,N*\ASJCF/L98C**
MF`KTL'@^>,72A@94J5*KR\C_`'C<J#<_C5:7[Q_12?%V5THYEB<UP&-A7Y'5
MPDL/.%&ES+W%0<(PE;E^)WIW?Q*H_>/T1LOC-\,-01'L_&FCW"N@91')-YAR
M`0/*,(D#8(^0H'!."H/%;5CX\T+5I4BTF2:^WM@3>1);PXSR?](6.;C(P1#A
MO49S7Y/?#\`RP`]-\0_-HQUZ]*_2SX3Z3I[:6+IK8-/&RA':24@`J3]PR>6>
M0.2A(QQ7Z!PKQ9G7$,J2Q%'+L,I*\W06(DVK)VC[64DOG?U[>]E6:XW,''VD
M,-33W]G[1O:+=N:_=_Y]O:0<@'U`/YTM(.GXG^9I:_2CZ0****`"BBB@`HHH
$H`__V3\_
`
end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
